3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
8
Uterine Cervical Neoplasms
2
Peritoneal Neoplasms
2
Fallopian Tube Neoplasms
2
Recurrence
1
Ovarian Diseases
1
Neoplasms by Site
1
Neoplasms
1
Endometrial Neoplasms
1
Endometrial Adenocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma
1
Interventions
Paclitaxel
7
Cisplatin
6
pembrolizumab
5
Carboplatin
5
Bevacizumab
5
liposomal doxorubicin
3
Gemcitabine
3
trebananib
2
niraparib
2
interferon gamma-1b
2
dostarlimab
2
catumaxomab
2
atezolizumab
2
anlotinib
2
Topotecan
2
Radiotherapy, Intensity-Modulated
2
Ocoxin
2
Itraconazole
2
Injections
2
Hyperthermic Intraperitoneal Chemotherapy
2
Drug Therapy
2
Docetaxel
2
vosaroxin
1
vistusertib
1
pertuzumab
1
peginterferon alfa-2b
1
olaparib
1
nintedanib
1
lanreotide
1
epothilone B
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
nintedanib
×
Gynecologic
×
Clear all
NCT01610869
2019-05-29
METRO-BIBF
University College, London
Phase 2
Completed
117 enrolled